Biotech Values

[drbio45]

Pharming provides update on outstanding shares

Pharming has needed to do some awful financings but their drug is better then the other ones approved for HAE. they will probably recieve European approval by the end of the month.




Companies:PHARMING GROUP NVPHARMING GRP NV LEID
Press Release Source: Pharming Group N.V. On Friday June 18, 2010, 12:10 pm EDT
LEIDEN, NETHERLANDS--(Marketwire - 06/18/10) -



Leiden, The Netherlands, June 18, 2010. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that its current number of outstanding shares has increased from 277,206,421 at June 2, 2010 to 285,691,836 as per today. The increase reflects an aggregate number of 8,485,415 shares issued in relation to various conversions of bonds issued in January 2010. As a result of these conversions, the original nominal value of the bonds issued in January 2010 in the amount of EUR7.5 million has decreased to EUR2.0 million today.

About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® - a product under development by Pharming's subsidiary DNage - is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin- out of DNage was initiated. Additional information is available on the Pharming website,http://www.pharming.com.